Immune checkpoint inhibitor for different age patients with NSCLC in efficacy: A systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immune checkpoint inhibitor for different age patients with NSCLC in efficacy: A systematic review and meta-analysis

Published:2024-04 Issue: Volume: Page:
ISSN:1015-9584
Container-title:Asian Journal of Surgery
language:en
Short-container-title:Asian Journal of Surgery

Author:

Zhang Qi,Liang Xiao-yan,Wang Ze-sheng,Sun An,Cao Tin-bao,Zhang Yu-Peng,Li Nan,Yi Tong-ying,Qu Kun-Peng

Funder

Natural Science Foundation of Gansu Province

Publisher

Elsevier BV

Reference63 articles.

1. Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update;Jonna;Discov Med,2019

2. Adjuvant and neoadjuvant immunotherapy in non-small cell lung cancer;Broderick;Thorac Surg Clin,2020

3. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices;Pennell;Am Soc Clin Oncol Educ Book,2019

4. Molecular therapeutic targets in non-small cell lung cancer;Sankar;Expert Rev Anticancer Ther,2020

5. Biomarkers in non-small cell lung cancer: perspectives of individualized targeted therapy;Aoki;Anti Cancer Agents Med Chem,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP